SS Innovations (Nasdaq: SSII) wins telesurgery approval in Indonesia, Philippines
Rhea-AI Filing Summary
SS Innovations International, Inc. reported that its SSi Mantra surgical robotic system has been approved for telesurgeries in Indonesia and the Philippines. The company highlighted that more than 150 cumulative telesurgeries have been successfully performed with SSi Mantra, primarily in India, underscoring growing real‑world use of its platform.
The update describes recent benchmarks, including 18 inter-hospital telesurgeries completed between two Indian cities in eight hours on February 14, 2026, and an earlier 12-hour telesurgery marathon with 24 procedures on December 23, 2025. SS Innovations also announced it will host the Global Multi-Specialty Robotic Surgery Conference 2026 in New Delhi from April 9-11, 2026, where over 20 live telesurgeries using SSi Mantra are planned.
Positive
- None.
Negative
- None.
Insights
New country approvals and growing telesurgery volume show momentum but no quantified financial impact yet.
SS Innovations secured approval for its SSi Mantra surgical robotic system to perform telesurgeries in Indonesia and the Philippines, expanding beyond its initial base in India. The company also cites more than 150 cumulative telesurgeries, including high-intensity sessions such as 18 procedures in eight hours and 24 in 12 hours.
These details indicate increasing clinical adoption and operational robustness of the SSi Mantra platform, especially in complex procedures like gastric bypass and gynecological surgeries. However, there are no revenue, pricing, or contract figures, so the direct financial effect of these approvals remains undefined in this disclosure.
The planned Global Multi-Specialty Robotic Surgery Conference 2026 in New Delhi, with over 20 live telesurgeries, may further showcase capabilities to surgeons and hospital decision‑makers. Subsequent company filings or updates would be needed to understand how this visibility translates into system placements or recurring instrument usage.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
|
|
||
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including
area code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each Class | Trading Symbol | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As used in this Current Report on Form 8-K (this “Current Report”), the terms “SSi,” “the Company,” “we,” “us” and “our” refer to SS Innovations International, Inc. and its subsidiaries.
Item 8.01 Other Events.
On March 18, 2026, the Company issued a press release announcing that its SSi Mantra surgical robotic system (the “SSi Mantra”) has been approved for telesurgeries in Indonesia and the Philippines and updating the number of telesurgeries performed utilizing the SSi Mantra.
The press release also announced the Global Multi-Specialty Robotic Surgery Conference 2026 to be hosted by the Company from April 9-11, 2026 in New Delhi, India.
A copy of the press release is included as Exhibit 99.1 to this Current Report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release, dated March 18, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: March 18, 2026 | SS INNOVATIONS INTERNATIONAL, INC. | |
| By: | /s/ Sudhir Srivastava | |
| Sudhir Srivastava, M.D. | ||
| Chairman and Chief Executive Officer | ||
2
Exhibit 99.1
SS Innovations’ SSi Mantra Surgical Robotic System Approved for Telesurgeries in Indonesia and the Philippines
Company surpasses milestone of 150 cumulative telesurgeries successfully performed with the SSi Mantra
Fort Lauderdale, FL – March 18, 2026 – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company’s SSi Mantra surgical robotic system has been approved for telesurgeries in Indonesia and the Philippines. The Company today also announced that more than 150 cumulative telesurgeries have been successfully performed utilizing the SSi Mantra surgical robotic system, primarily in India.
Among recent highlights showcasing the advanced capabilities of the SSi Mantra, a total of 18 inter-hospital telesurgeries were performed between two Indian cities during an eight-hour period on February 14, 2026, including 13 gastric bypass procedures performed by Dr. Mohit Bhandari from Mohak Bariatrics and Robotics in Indore, India and 5 complex gynecological surgeries performed by Dr. Priya Bhave Chittawar from HER Health Hospital in Bhopal, India. All procedures were conducted using the SSi MantrAsana Tele Surgeon Console, a compact self-contained chair-based version of the larger SSi Mantra surgeon command center that enables portability, requires less space, and facilitates the performance of telesurgeries from a wide range of settings, including physician offices.
This feat comes on the heels of a robotic telesurgery marathon that took place from SS Innovation’s headquarters on December 23, 2025, during which nine surgeons utilized the SSi Mantra to perform 24 telesurgeries within a 12-hour period on patients located across multiple locations in India. The telesurgeries consisted of ten different types of procedures, including intricate cardiac surgeries.
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “The SSi Mantra surgical robotic system continues to pioneer telesurgery, not merely in concept but in real-world practice and rapidly growing adoption by leading physicians. We are thrilled to receive approval for telesurgeries utilizing the SSi Mantra in two new markets: Indonesia and the Philippines. We also are pleased to surpass the milestone of more than 150 telesurgeries successfully performed with the SSi Mantra, indicating that we are gaining significant traction in enabling state-of-the-art remote surgical care. The SSi Mantra’s advanced telesurgery capabilities empower the cross-sharing of physicians’ expertise and dismantle traditional geographical barriers to care, furthering our mission of driving equitable access to quality healthcare.”
Global Multi-Specialty Robotic Surgery Conference 2026 (“SMRSC 2026”)
On April 9-11, 2026, SS Innovations is hosting SMRSC 2026 in New Delhi, India, where distinguished surgeons, global thought leaders and prominent innovators in robotic and minimally invasive surgery will convene to discuss the shape and future of the field. During the conference, more than 20 live telesurgeries will be performed using the SSi Mantra, spanning multiple specialties and led by top experts in robotic surgery. To register for the conference, please visit: https://ssinnovations.com/SMRSC_2026/register/.
About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.
About the SSi Mantra
The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with many advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures.
Forward Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
Investor Contact:
The Equity Group
Kalle Ahl, CFA
T: (303) 953-9878
kahl@theequitygroup.com
Devin Sullivan, Managing Director
T: (212) 836-9608
dsullivan@theequitygroup.com
Media Contact:
RooneyPartners LLC
Kate Barrette
T: (212) 223-0561
kbarrette@rooneypartners.com
FAQ
What did SS Innovations (SSII) announce in its March 18, 2026 8-K?
Which new markets approved the SSi Mantra for telesurgery?
How many telesurgeries have been performed with SSi Mantra so far?
What is the Global Multi-Specialty Robotic Surgery Conference 2026 for SSII?
What capabilities of the SSi Mantra system were highlighted in this disclosure?
Where is SS Innovations headquartered and what is its strategic focus?
Filing Exhibits & Attachments
4 documents